4 clinical trials for different applications with novel drugs (CTIX), or 1 clinical trial for a failed Alzheimer's drug that was abandoned by the original developer (AXON) -- that's the choice. 320 million in the bank does not warrant a market cap of 1.77 Billion when you have no drug to develop that has a chance of approval. (AXON's drug goes down the same failed pathway that many dozens of other failed drugs have tried.) If AXON's market cap were 640 million, I'd think that was reasonable at this point, to assume that they'd deploy that money to find and develop something. But 1.77 billion when they really have nothing going that's got a chance of success -- crazy.